Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future...

Area of Science:

• Medicinal Chemistry
• Virology
• Drug Discovery

Background:

• The C-X-C chemokine receptor type 4 (CXCR4) is crucial for Human Immunodeficiency Virus type 1 (HIV-1) entry into host cells.
• CXCR4 represents a promising drug target for anti-AIDS therapies due to its essential role and fewer mutations compared to traditional targets.
• CXCR4 antagonists exhibit no cross-resistance with other antiviral drug classes, offering a valuable alternative treatment strategy.

Purpose of the Study:

• To review recent advancements in the discovery of CXCR4 antagonists.
• To highlight the evolution and structure-activity relationships (SAR) of representative CXCR4 antagonists.
• To introduce classical and novel medicinal chemistry strategies employed in CXCR4 antagonist development.

Main Methods:

• Literature review of recent scientific publications on CXCR4 antagonists.
• Analysis of structure-activity relationships for key CXCR4 antagonist compounds.
• Discussion of medicinal chemistry strategies and novel methodologies in drug discovery.

Main Results:

• Numerous small molecule CXCR4 antagonists with diverse chemical scaffolds have been identified.
• Significant progress has been made in understanding the SAR of these antagonists.
• Various medicinal chemistry approaches have been successfully applied to develop CXCR4 antagonists.

Conclusions:

• CXCR4 antagonists are a promising class of therapeutics for HIV-1 infection.
• Continued research into CXCR4 antagonist evolution and SAR will drive the development of more effective anti-AIDS drugs.
• Novel medicinal chemistry strategies are essential for discovering next-generation CXCR4-targeting agents.